French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel <i>versus</i> gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients.

11 , 12 No randomized phase III study neither compared FOLFIRINOX versus GEM-NAB directly, but retrospective studies showed a trend toward greater OS in patients treated with FOLFIRINOX. 13 , 14 Recently, the first results of NALIRIFOX versus GEM-NAB, presented during ASCO congress, reported OS in favor of NALIRIFOX. 15 These data are opposed to other phase III recent trial, stopped for futility, showing a signal in favor of GEM-NAB over FOLFIRINOX regimen. 16 These data do not argue for a reimbursement of GEM-NAB in first line in France.

also in 53,322 other papers